China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has entered into a strategic partnership with compatriot firm Yoltech Therapeutics Co., Ltd. The collaboration aims to advance the development of gene editing products, mRNA drugs, and related services in both domestic and international markets.
Focus on Next-Generation Gene Editing Therapies
Yoltech Therapeutics specializes in the development of next-generation in vivo gene editing therapies. The company is known for its next-generation gene editing tool, YolCas, and base editing tool, YolBE. Yoltech’s product portfolio spans a range of therapeutic areas, including genetic disorders, cardiovascular diseases, metabolic disorders, and infectious diseases.
Perfect mRNA Bio’s Core Competencies and Offerings
Perfect mRNA Biotechnology is engaged in the development of mRNA vaccines, cell gene therapy (CGT), and in vitro diagnosis (IVD). The company’s core raw materials include a variety of chemical raw materials such as conventional Nucleoside triphosphate (NTPs), modified Nucleoside triphosphate (e.g., N1 Me puTP), mRNA cap Structural analog, deoxy Nucleoside triphosphate (dNTPs), and core high-end biological enzymes like T7 RNA polymerase, RNA enzyme inhibitor, hot start DNA polymerase, and MMLV reverse transcriptase.
Combining Expertise for Global Impact
The partnership between Perfect mRNA Bio and Yoltech Therapeutics combines their respective expertise in mRNA technology and gene editing, positioning them to make significant contributions to the fields of genetic medicine and therapy. This collaboration is expected to accelerate the development and commercialization of innovative treatments for a wide range of diseases.-Fineline Info & Tech
